SEARCH

SEARCH BY CITATION

References

  • Beckers HJ, Schouten JS, Webers CA, van der Valk R & Hendrikse F (2008): Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol 246: 148590.
  • Burr J, Mowatt G, Hernández R et al. (2007): The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 11: iii–iv, ix–x, 1190.
  • Burr JM, Botello-Pinzon P, Takwoingi Y, Hernández R, Vazquez-Montes M, Elders A, et al. (2012): Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. Health Technol Assess 16: 1274.
  • Caro JJ, Moller J & Getsios D (2010): Discrete event simulation: the preferred technique for health economic evaluations? Value Health 13: 105660.
  • Cleemput I, Neyt M, Thiry N, De Laet C & Leys M (2008): KCE reports 100C (D/2008/10.273/96). Threshold values for cost-effectiveness in health care Health Technology Assessment (HTA). Brussels, Belgium: Belgian Health Care Knowledge Centre (KCE).
  • Coleman AL & Miglior S (2008): Risk factors for glaucoma onset and progression. Surv Ophthalmol 53(Suppl 1): S310.
  • Dutch Healthcare Authority (Nederlandse Zorgautoriteit) (2007): Maximum tariffs (Tariefbeschikking maximumtarieven extramurale zorg in het tweede en derde compartiment).
  • Ernest PJ, Busch MJ, Webers CA, Beckers HJ, Hendrikse F, Prins MH & Schouten JS (2013): Prevalence of end-of-life visual impairment in patients followed for glaucoma. Acta Ophthalmol 91: 738743.
  • European Glaucoma Society (2008). Terminology and guidelines for glaucoma, 3rd Edn. Savona, Italy: Dogma.
  • Felli JC & Hazen GB (1998): Sensitivity analysis and the expected value of perfect information. Med Decis Making 18: 95109.
  • Foundation for pharmaceutical statistics (Stichting Farmaceutische Kengetallen) (2007): Data and facts 2007 (Data en feiten 2007).
  • Gafni A & Birch S (2006): Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 62: 2091100.
  • Gordon M, Beiser J, Brandt J et al. (2002): The Ocular Hypertension Treatment Study; Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 714720.
  • Gordon MO, Torri V, Miglior S et al. (2007): Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 114: 109.
  • Heeg GP & Jansonius NM (2009): The groningen longitudinal glaucoma study III. The predictive value of frequency-doubling perimetry and GDx nerve fibre analyser test results for the development of glaucomatous visual field loss. Eye 23: 164752.
  • Heijl A. (2013): The times they are a-changin’: time to change glaucoma management. Acta Ophthalmol 9: 929.
  • Heijl A & Bengtsson B (2000): Long-term effects of timolol therapy in ocular hypertension: a double-masked randomised trial. Graefes Arch Clin Exp Ophthalmol 238: 877883.
  • Kass M, Heuer D, Higginbotham E et al. & Group OHTs (2002): The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701713.
  • Kobelt G & Jönsson L (1999): Modeling cost of treatment with new topical treatments for glaucoma. Int J Technol Assess Health Care 15: 207219.
  • Koopmanschap MA, Rutten FF, van Ineveld BM & van Roijen L (1995): The friction cost method for measuring indirect costs of disease. J Health Econ 14: 17189.
  • Kwon YH, Fingert JH, Kuehn MH & Alward WL (2009): Primary open-angle glaucoma. N Engl J Med 360: 111324.
  • Kymes SM, Kass MA, Anderson DR, Miller JP & Gordon MO (2006): Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 141: 9971008.
  • Maier P, Funk J, Schwarzer G, Antes G & Falck-Ytter Y (2005): Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 331: 134.
  • Narayanaswamy A., et al. (2007): A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan® in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 55: 127131.
  • National Collaborating Centre for Acute Care (2009): Glaucoma: diagnosis and management of chronic open-angle glaucoma and ocular hypertension. London: National Collaborating Centre for Acute Care.
  • Olsen J, Berdeaux G & Skov J. (2013): Glaucoma costs in Denmark in treatment naive patients. Acta Ophthalmol 91: 2531.
  • Oostenbrink J, Rutten-van Mölken M & Opdenoordt T (1999): The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in the Netherlands: an observational study of costs and initial treatment success based on retrospective chart review. Doc Ophthalmol 98: 285299.
  • Oostenbrink J, Rutten-van Mölken M & Sluyter-Opdenoordt T (2001): Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 10: 184191.
  • Oostenbrink J, Bouwmans C, Koopmanschap M & Rutten F (2004): Manual for costing research (Handleiding voor kostenonderzoek; Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg.). Diemen, The Netherlands: Health Care Insurance Board (CVZ).
  • Peeters A, Schouten JS, Webers CA, Prins MH, Hendrikse F & Severens JL (2008): Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist. Eye 22: 35462.
  • Peeters A, Webers C, Prins M, Zeegers M, Hendrikse F & Schouten J (2010): Quantifying the effect of intra-ocular pressure reduction on the occurrence of glaucoma. Acta Ophthalmol 88: 511.
  • Raad voor Volksgezondheid en Zorg (Council for Public Health and Health Care) (2006): Zinnige en duurzame zorg (Sensible and sustainable care). Zoetermeer: RVZ.
  • Rein D, Wittenborn J, Lee P, Wirth K, Sorensen S, Hoerger T & Saaddine J (2009): The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology 116: 823832.
  • Rodenburg-Van Dieten H (2005): Guidelines for pharmacoeconomic research (version 2006). Diemen: Health Insurance Board.
  • Stewart WC, Stewart JA, Nassar QJ & Mychaskiw MA (2008): Cost-effectiveness of treating ocular hypertension. Ophthalmology 115: 948.
  • Takada Y, Okada Y, Fujita N & Saika S (2012): A patient with corneal epithelial disorder that developed after administration of a latanoprost generic, but not a brand-name drug, eye drop. Case Reports. Ophthalmol Med 2012, Article ID 536746.
  • Traverso CE, Walt JG, Kelly SP et al. (2005): Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 89: 12459.
  • Tuulonen A. (2013): Challenges of glaucoma care – high volume, high quality, low cost. Acta Ophthalmol 91: 35.
  • Van Gestel A, Severens J, Webers C, Beckers H, Jansonius N & Schouten J (2010a): Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health 13: 358367.
  • Van Gestel A, Webers C, Beckers H, Van Dongen C, Severens J, Hendrikse F & Schouten J (2010b): The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye 24: 17591769.
  • van Gestel A, Webers CA, Severens JL Beckers HJ Jansonius Nm, Hendrikse F and Schouten JS (2012): The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol 90: 2031.
  • Van Hout BA, Al M, Gordon G & Rutten F (1994): Costs, effects and C/E ratios alongside a clinical trial. Health Econ 3: 309319.
  • Verweij A, Barnhoorn M & Van den Berg M (2008): Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid (Exploration of future public health. National compass of public health). Wat is de kosteneffectiviteit van preventie? (What is the cost-effectiveness of prevention). Bilthoven: Rijksinstituut voor volksgezondheid en milieu (Research for man and environment).